- Home
- PRVA vs TARS Comparison
PRVA vs TARS Comparison
Compare PRVA & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRVA | TARS |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRVA | TARS |
|---|---|---|
| Price | $23.29 | $71.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | $30.50 | ★ $76.56 |
| AVG Volume (30 Days) | ★ 634.0K | 544.8K |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $2,042,569,000.00 | $366,100,000.00 |
| Revenue This Year | $104.97 | $147.34 |
| Revenue Next Year | $9.92 | $53.50 |
| P/E Ratio | $170.33 | ★ N/A |
| Revenue Growth | 19.01 | ★ 182.44 |
| 52 Week Low | $18.77 | $38.51 |
| 52 Week High | $26.51 | $85.25 |
Technical Indicators
Market Signals| Indicator | PRVA | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 26.51 |
| Support Level | $22.59 | $76.91 |
| Resistance Level | $24.00 | $76.22 |
| Average True Range (ATR) | 0.74 | 3.15 |
| MACD | -0.04 | -1.09 |
| Stochastic Oscillator | 35.32 | 0.12 |
Price Performance
Historical ComparisonAbout PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.